Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus

OBJECTIVE: Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine‐QR, a dopamine‐agonist antidiabetes medication, on elevated resting heart rate (RHR) (a marker of SNS overactivity in metabolic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamarthi, Bindu, Vinik, Aaron, Ezrokhi, Michael, Cincotta, Anthony H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947713/
https://www.ncbi.nlm.nih.gov/pubmed/31922028
http://dx.doi.org/10.1002/edm2.101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947713/
https://www.ncbi.nlm.nih.gov/pubmed/31922028
http://dx.doi.org/10.1002/edm2.101

Ejemplares similares